ArticleStem cell research & therapy2024
CGF therapy: bridging androgenetic alopecia observations to psoriasis treatment via IL-17 pathway.
Article in Stem cell research & therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Effect of autologous concentrated growth factor on bedsore wounds in elderly patients with diabetes: a case-control study.Frontiers in endocrinology · 2025Trial
- Evolution and mechanistic insights of platelet-derived products in temporomandibular joint regeneration.Frontiers in cell and developmental biology · 2026Review
- Treatment for Filler-Induced Alopecia with Concentrated Growth Factors.Clinical, cosmetic and investigational dermatology · 2026Article
- Efficacy and Safety Analysis of Concentrated Growth Factor Combined with Photorejuvenation for Sensitive Skin Patients: A Retrospective Cohort Study.Clinical, cosmetic and investigational dermatology · 2026Article
- Clinical Efficacy of Composite Autologous Chylated Fat and Concentrated Growth Factors for Treating Postinjection Alopecia After Facial Fillers: A Single-Center Retrospective Study.Journal of cosmetic dermatology · 2025Article
- The evolution of three generations of platelet concentrates products: a leap from classical formulations to the era of extracellular vesicles.Frontiers in bioengineering and biotechnology · 2025Review
- Advances in the Molecular Pathogenesis and Targeted Therapy of Psoriasis : Molecular Pathogenesis of Psoriasis.Galen medical journal · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
introductionConcentrated Growth Factor (CGF), rich in CD34 + stem cells, is widely used in treatments for androgenetic alopecia and skin rejuvenation due to its immune-modulating properties. Psoriasis, a chronic inflammatory skin condition, presents significant treatment challenges, particularly for patients who cannot use biologics due to conditions such as cancer and lesions resistant to treatments. The potential of CGF in treating psoriasis is promising, given its broad immunoregulatory effects which confirmed in our previous androgenetic alopecia work.
methodsWe evaluated the impact of CGF on IL-17 levels in two contexts: patients treated for androgenetic alopecia and a psoriasis mouse model. Twelve patients received three monthly injections of CGF, with serum IL-17 levels measured before and after treatment. In the psoriasis mouse model, groups were treated with CGF, and outcomes were assessed using the Psoriasis Area and Severity Index (PASI), skin barrier scores, histological analysis, and RNA sequencing. Additionally, in vitro experiments applied CD34 + cells from CGF to keratinocytes to measure levels of TNF-α, IFN-γ, IL-23, and IL-17.
resultsIn patients with androgenetic alopecia, three monthly CGF injections resulted in significantly reduced serum IL-17 levels. In the psoriatic mouse model, CGF-treated groups exhibited lower PASI scores and improved skin barrier scores compared to controls. Histological analysis revealed enhanced skin characteristics, while RNA sequencing demonstrated downregulated IL-17 and upregulated CD34 expression, as well as improved expression of barrier-related genes. In vitro, the application of CD34 + cells from CGF to keratinocytes led to a significant reduction in TNF-α, IFN-γ, IL-23, and IL-17 levels, indicating strong anti-inflammatory effects. A clinical case of a psoriasis patient unresponsive to IL-23 therapy (Guselkumab) showed significant improvement following CGF treatment.
conclusionThese findings indicate that CGF could serve as an effective and versatile treatment for psoriasis, especially for patients who have already undergone biologic therapies but continue to experience resistant lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.